Nasdaq Rally Hits Speed Bump as Tech Stocks Wobble – Fed Warning and AI Jitters Shake Markets (Sept 24–25, 2025)

NYSE Today — Nov. 5, 2025: Tech‑led rebound, Exzeo’s muted NYSE debut (XZO), and what ADP & ISM say about the outlook

At a glance

  • Stocks bounce after Tuesday’s sell‑off as megacaps, retailers and financials recover; midday gains: S&P 500 +0.8%, Dow +289 pts (+0.6%), Nasdaq +1.2%. [1]
  • New listing: Insurance‑tech firm Exzeo Group (NYSE: XZO) opens flat at $21, matching its IPO price and implying ~$1.9B valuation after raising $168M. [2]
  • Macro drivers:ADP private payrolls +42,000 (Oct) and ISM Services PMI 52.4, both above expectations; Treasury yields firm. [3]
  • Policy watch:Supreme Court hears challenges to Trump‑era emergency tariffs; multiple justices signal skepticism—an overhang for trade‑sensitive stocks. [4]

Market recap: Risk appetite returns, breadth improves

U.S. equities turned higher by early afternoon Wednesday, reversing much of Tuesday’s drop. Gains were broad‑based with tech leadership and contributions from retail and financials. The S&P 500 rose ~0.8%, the Dow added nearly 300 points, and the Nasdaq outperformed. [5]

On the NYSE’s own midday desk note, strategists flagged strong breadth, small‑cap outperformance, and firmer yields following stronger‑than‑expected data, while noting that tariff‑case headlines were in focus. [6]

Biggest NYSE movers to watch

  • McDonald’s (NYSE: MCD) climbed after reporting solid sales momentum.
  • International Flavors & Fragrances (NYSE: IFF) jumped on a profit beat.
  • Live Nation (NYSE: LYV) fell after earnings disappointed.
    (Performance snapshots from the AP’s Wednesday market update.) [7]

New listing: Exzeo’s quiet debut on the Big Board

Insurance‑technology provider Exzeo Group began trading on the NYSE under ticker XZO, opening unchanged at $21—its offer price—after raising $168 million (8 million shares) and valuing the company around $1.91 billion. Parent HCI Group retains a majority stake. The subdued open contrasts with stronger 2025 receptions for other insurance names, underscoring a more selective IPO tape. [8]

Context: The listing adds to a tentative reopening of the U.S. IPO window after a choppy year for risk assets and policy uncertainty. [9]


Macro snapshot: Data firm up into year‑end

  • Jobs:ADP reported +42,000 private‑sector jobs in October (vs. economists’ lower consensus), a modest rebound from September’s decline and another sign of a cooling—but not collapsing—labor market. [10]
  • Services activity:ISM Services PMI printed 52.4 for October, returning to expansion and beating forecasts; traders read the report as growth‑positive even as the employment sub‑index remained soft. [11]

Together, the releases helped steady sentiment after Tuesday’s tech‑led slide, even as Treasury yields pushed higher on the stronger prints. [12]


Policy & legal overhang: Supreme Court takes up emergency tariffs

The U.S. Supreme Court heard challenges to the administration’s use of emergency powers to impose sweeping tariffs. Reporting from the courtroom described skepticism across the bench—including from several conservatives—about the legal footing for unilateral, broad tariffs under the IEEPA statute. A ruling in the months ahead could reshape the trade backdrop for import‑reliant sectors and consumer prices. [13]


Why it matters for NYSE investors

  • Earnings + macro > rates—for now: A steady cadence of reports (from mega‑caps to consumer bellwethers) plus positive ADP/ISM surprises is offsetting Tuesday’s valuation jitters. [14]
  • Listing conditions: Exzeo’s flat open is a reminder that investors are discriminating on growth quality and profitability—even in sectors (insurance/insurtech) that have priced well this year. [15]
  • Tariff path: If the Court narrows presidential tariff powers, it could reduce a key policy volatility source for supply chains and inflation—material inputs for equity multiples and earnings. [16]

What’s next

Traders continue to parse corporate results and late‑day guidance, with attention on bellwethers across tech, consumer and financials. Major outlets highlighted McDonald’s (today), and Qualcomm/Allstate among names in focus around the close and after‑hours. [17]


Sources & methodology

This roundup focuses on NYSE‑relevant developments for Wednesday, Nov. 5, 2025, synthesizing intraday market color, fresh macro data, the day’s notable NYSE listing, and policy/legal risk likely to influence trading on the exchange.

Primary sources used in this report:

  • AP and Reuters for market moves and data context. [18]
  • Reuters for Exzeo (XZO) IPO pricing and trading debut. [19]
  • ADP and ISM official releases for economic indicators. [20]
  • NYSE strategist note for intraday breadth/yield commentary. [21]
  • AP, Washington Post, Politico for Supreme Court tariff‑case coverage. [22]
  • WSJ futures/earnings daybook. [23]
Top 10 AI Stocks to Watch: Cathie Wood

References

1. apnews.com, 2. www.reuters.com, 3. www.reuters.com, 4. apnews.com, 5. apnews.com, 6. www.nyse.com, 7. apnews.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.prnewswire.com, 12. www.nyse.com, 13. apnews.com, 14. apnews.com, 15. www.reuters.com, 16. apnews.com, 17. www.wsj.com, 18. apnews.com, 19. www.reuters.com, 20. mediacenter.adp.com, 21. www.nyse.com, 22. apnews.com, 23. www.wsj.com

Stock Market Today

  • Energy Recovery (ERII) Q3 CY2025: Revenue Beats but Margin Drops, Stock Dips
    November 5, 2025, 10:32 PM EST. Energy Recovery (ERII) posted Q3 CY2025 results that beat revenue expectations $32M vs $29.94M estimates, yet YoY revenue declined 17.1% to $32 million. Non-GAAP EPS was $0.12, beating consensus by $0.02. Adjusted EBITDA came in at $6.8M vs $7.21M expected, with an operating margin of 11.4% (down from 18.3% a year ago). Free cash flow was -$3.5M vs -$3.17M prior year. Market cap around $873M. Long-term growth shows 5-year revenue CAGR ~3.8%, while the last two years' pace rose to ~9.2%, suggesting momentum. Analysts project ~31.1% revenue growth over the next 12 months, driven by newer products and services. Stock reaction followed the quarter's results.
  • Array (ARRY) Surges in Q3 on Revenue Beat and Higher Guidance
    November 5, 2025, 10:30 PM EST. Array (ARRY) delivered a strong Q3 beat with revenue of $393.5 million, up 70% YoY and 26.3% above estimates. Adjusted EPS came in at $0.30 vs $0.20 consensus (a 48.9% beat). Adjusted EBITDA was $72.19 million, vs $56.76 million expected (an 18.3% margin and 27.2% beat). The company raised its full-year revenue guidance to a midpoint of $1.27 billion (up from $1.20 billion, +5.6%) and nudged Adjusted EPS guidance to $0.67. EBITDA guidance is $190 million at the midpoint, below some estimates ($196 million). Operating margin improved to 11.6% from -57.3% a year ago; Free Cash Flow Margin is 5.6%, down from 24.1%. The APA acquisition completed in August underpins expanded solar offerings.
  • Dutch Bros stock climbs after solid Q3, lifts full-year sales outlook
    November 5, 2025, 10:28 PM EST. Shares of Dutch Bros rose about 3% after-hours as the coffee chain posted Q3 earnings that topped expectations. It reported same-store sales growth of about 5.7%, ahead of the ~4% consensus, and beat on both top and bottom line results. Management also raised its full-year guidance, targeting around 5% same-store sales growth for the year. The beat is driven by a drive-through model, energy drinks, and menu experiments as the chain expands into food. Dutch Bros continues to push rapid store growth and a differentiated customer experience, setting it apart from other coffee peers in a tougher environment.
  • Halozyme Therapeutics (HALO) Valuation Update: Is HALO Undervalued After a Strong Rally?
    November 5, 2025, 10:26 PM EST. Halozyme Therapeutics has surged about 40% year-to-date, fueling investor interest in its valuation. Our latest read points to a fair value of $74.44, suggesting the stock remains undervalued versus the recent close around $68.05, with potential upside if growth drivers materialize. The catalyst is the ENHANZE subcutaneous delivery platform expanding adoption (e.g., DARZALEX SC in the US and Phesgo for at-home use), which could boost royalty revenues and drive net margin expansion over time. However, risks linger from patent challenges and heightened competition that could affect future growth. Investors should weigh this mix and consider how the biotech delivery shift supports Halozyme's long-term thesis.
  • Robinhood earnings: Prediction markets could be a major growth driver
    November 5, 2025, 10:24 PM EST. Robinhood reported solid earnings with top- and bottom-line beats and a sharper uptick in net deposits in September. The stock softened early on amid lofty expectations and news of a CFO retirement. Beyond the quarter, the debate focused on prediction markets as a potential growth engine. Analysts say diversification away from volatile trading could smooth revenue and extend earnings visibility. While currently small, these markets-covering sports, politics, and macro forecasts-could scale meaningfully, especially if institutional money flows in. A successful push hinges on regulatory clarity and user engagement, but the move could redefine growth for Robinhood outside traditional trading.
Nasdaq Frenzy: Tech Titans’ AI-Fueled Surge Hits Records Ahead of Fed Cut & Earnings Bonanza
Previous Story

Nasdaq Today (Nov. 5, 2025): Tech Rebounds on ADP Beat; AMD Rises, Super Micro Sinks

NYSE Today — Nov. 5, 2025: Tech‑led rebound, Exzeo’s muted NYSE debut (XZO), and what ADP & ISM say about the outlook
Next Story

Ethereum Price Today (Nov 5, 2025): ETH Rebounds Toward $3.46K After $1B+ Liquidations; ETFs Log Fifth Straight Day of Outflows

Go toTop